

Record: 1

Title: Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.

Authors: Hargrove JT; Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee.

Maxson WS

Wentz AC

Burnett LS

Source: Obstetrics And Gynecology [Obstet Gynecol] 1989 Apr; Vol. 73 (4), pp. 606-12.

Publication Type: Comparative Study; Journal Article

Language: English

Journal Info: *Publisher:* Lippincott Williams & Wilkins *Country of Publication:* United States *NLM ID:* 0401101 *Publication Model:* Print *Cited Medium:* Print *ISSN:* 0029-7844 (Print) *Linking ISSN:* 00297844 *NLM ISO Abbreviation:* Obstet Gynecol *Subsets:* Core Clinical (AIM); MEDLINE

Imprint Name(s): *Publication:* 2004- : Hagerstown, MD : Lippincott Williams & Wilkins *Original Publication:* New York.

MeSH Terms: Menopause*

Estradiol/*therapeutic use

Progesterone/*therapeutic use

Cholesterol/blood ; Climacteric/drug effects ; Delayed-Action

Preparations ; Drug Administration Schedule ; Drug Combinations

; Estrogens, Conjugated (USP)/therapeutic use ; Female ; Humans

; Medroxyprogesterone/analogs & derivatives

; Medroxyprogesterone/therapeutic use ; Medroxyprogesterone Acetate

; Middle Aged ; Pilot Projects

Abstract: The safety and efficacy of a daily combination of micronized estradiol (E2) (0.7-1.05 mg) and progesterone (200-300 mg) were evaluated in ten menopausal women with moderate to severe vasomotor symptoms and/or vaginal atrophy over a 12-month study interval. For comparison, five similar women were placed on conjugated estrogens, 0.625 mg daily, and medroxyprogesterone acetate, 10 mg daily, for the first 10 days of each calendar month for 12 months. Patients were evaluated at 0, 1, 3, 6, and 12 months. Estrogens rose significantly from baseline in both groups (P less than .01). Progesterone increased significantly above baseline in the E2 and progesterone group (P less than .01), but did not change in the conjugated estrogens and medroxyprogesterone acetate users. All women on E2 and progesterone had a decrease in total cholesterol and an increase in high-density lipoprotein cholesterol from baseline (P less than .01). Those on conjugated estrogens and medroxyprogesterone acetate had no significant change from baseline in total cholesterol; however, they did have an increase in high-density lipoprotein cholesterol values (P less than .01). In the E2 and

progesterone group, the endometrial histology became completely quiescent and there was no uterine bleeding after 6 months of observation. Four of five women on conjugated estrogens and medroxyprogesterone acetate continued regular withdrawal bleeding throughout the study period, but no endometrial hyperplasia was encountered. This study demonstrates that the daily administration of a combination of micronized E2 and progesterone results in symptomatic improvement, minimal side effects, an improved lipid profile, and amenorrhea without endometrial proliferation or hyperplasia in menopausal women.

Substance Nomenclature: 0 (Delayed-Action Preparations)
0 (Drug Combinations)
0 (Estrogens, Conjugated (USP))
4G7DS2Q64Y (Progesterone)
4TI98Z838E (Estradiol)
97C5T2UQ7J (Cholesterol)
C2QI4IOI2G (Medroxyprogesterone Acetate)
HSU1C9YRES (Medroxyprogesterone)

Entry Date(s): *Date Created:* 19890401 *Date Completed:* 19890427 *Latest Revision:* 20131121

Update Code: 20181210

PMID: 2538787

Database: MEDLINE Complete